Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis-Reference-Cited by-同舟云学术

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

Published:2021-03 Issue:3 Volume:24 Page:377-387
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Konidaris Gerasimos,Paul Eleanor,Kuznik Andreas,Keeping Sam,Chen Chieh-I,Sasane Medha,Xu Yingxin,Atsou Kokuvi,Ayers Dieter,Ruiz Emily S.,Khushalani Nikhil I.,Cope Shannon

Funder

Regeneron Pharmaceuticals

Sanofi

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference50 articles.

1. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012;Rogers;JAMA Dermatol,2015

2. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods;Kauvar;Dermatol Surg,2015

3. Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC);Bossi;J Clin Oncol,2017

4. Association of disease recurrence with survival outcomes in patients with cutaneous squamous cell carcinoma of the head and neck treated with multimodality therapy;Sun;JAMA Dermatol,2019

5. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park Experience and a review of the literature;Jarkowski;Am J Clin Oncol,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma;Scientific Reports;2024-07-31

2. First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis;Scientific Reports;2024-06-24

3. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients;Frontiers in Immunology;2024-04-22

4. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer;Medicine;2024-04-19

5. A cost-effective approach to measurements of fluorophore temperature sensitivity and temperature change with reasonable accuracy;Scientific Reports;2024-03-21